Abstract TMP119: Evaluation of Cognitive Function and Plasma Biomarkers in a Microemboli-Based VCID Model in Rats: Applying Clinical Recommendations From MarkVCID and the Lacunar Intervention Trial-2 (LACI-2) to a Preclinical Model
Stroke Journal
FEBRUARY 1, 2024
Diabetes doubles the risk of VCID. We showed that diabetic but not control rats develop a progressive cognitive decline in a microemboli (ME) model of VCID. Behavioral deficits observed in the untreated diabetic rats were not noted in the treated group. Some of the biomarkers were unchanged (Table).
Let's personalize your content